DETECT Study: Understanding Diabetes in Pancreatic Conditions
This observational study, called DETECT, is looking at how a mixed meal test can help doctors better understand and diagnose Type 3c diabetes. This type of diabetes is linked to conditions like pancreatic cancer and chronic pancreatitis (long-lasting inflammation of the pancreas). Researchers want to see how your body's response to a meal, including hormones like insulin and glucagon, differs in people with these conditions compared to those with Type 2 diabetes. The study aims to enroll 775 participants between 30 and 84 years old who have signed an informed consent form. This study is not testing a new treatment, but rather observing how different groups respond to a mixed meal.
- Study design
- This is an observational study, meaning researchers will be watching and collecting information without giving any specific treatments. It plans to include 775 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will monitor regulatory documents for 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT03460769
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Recruiting
Not specifiedAges 30–84ObservationalM.D. Anderson Cancer CenterInvestigator-initiated
~775 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Data Management and Monitoring
At a glance
Recruiting sites
1 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
Measured over 3 years
Conditions
Where it's being run
10 sites across 7 statesCalifornia2
Minnesota2
Texas2
Florida1
Indiana1
Ohio1
Pennsylvania1
Study leadership
- Suresh Chari, MBBS · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
All Participants must sign an informed consent indicating that they are aware of the investigational nature of this study. Participants must have signed an authorization for the release of their protected health information.
Participants must be ages ≥30 and \<85.
Participants must have a diagnosis of one of the following based on study definitions;
New Onset Diabetes (\<3 years) in participants with Pancreatic Cancer (PDAC);
New Onset Diabetes (\<3 years) in participants with Chronic Pancreatitis;
New Onset Diabetes (\<3 years) in participants without Pancreatic disease (i.e., T2DM)
Long standing T2DM (≥3 years) without Pancreatic disease
Long standing diabetes (≥3 years) in participants with PDAC
Long standing diabetes (≥3 years) participants with chronic pancreatitis
non-diabetic participants with PDAC
non-diabetic participants with chronic pancreatitis
non-diabetic controls without Pancreatic disease
Exclusion
Participants must not have any significant medical illnesses (including diabetes) that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the Participant's ability to tolerate study interventions.
Diabetes not stable enough to permit holding of diabetes medications in Participants undergoing mixed meal tolerance testing.
Participants taking higher doses of insulin (≥0.75 unit/kg/day). \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\]
Participants in the non-pancreatic disease subgroup on longer acting agents, including thiazolidinediones and once-weekly GLP-1 agonists (Bydureon \[exenatide\], Ozempic \[semaglutide\], Trulicity \[dulaglutide\]). \[Criterion is not applicable for Participants in the CP and PDAC groups\].
Participants currently receiving oral steroid medications.
Hospitalization for acute pancreatitis within 2 months before study visit. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\]
The presence of a symptomatic cyst in Participants with CP. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection; this includes cancer arising from a mucinous cystic lesion\].
Any Participant with a known pancreatic cancer histologic subtype other than adenocarcinoma (e.g., Participants with pancreatic neuroendocrine tumors are excluded).
Previous pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure). \[Criterion is not applicable for CP Participants with diabetes who have a history of pancreaticoduodenectomy, pancreaticojejunostomy, distal pancreatectomy, or Frey\].
Previous treatment for pancreatic cancer, including chemotherapy or radiation.
Previous vagotomy or gastric surgery, including endoscopic gastric reduction procedures. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
Previous diagnosis of gastroparesis. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
Participants on treatment for any cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).
Allergy or intolerance to ingredients in Boost drink in Participants undergoing mixed meal testing (see Appendix 13.9) \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
What this trial measures
- Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)3 years
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center will monitor protocol and regulatory compliance at all participating institutions.